A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Navicixizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors OncoMed Pharmaceuticals
- 18 Oct 2017 Planned End Date changed from 1 May 2018 to 1 Mar 2018.
- 25 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 May 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History